The pharmaceutical landscape for HER2-positive metastatic breast cancer has undergone a significant transformation with the FDA's approval of ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab as a first-line treatment—marking the first new therapeutic option approved in more than a decade for this indication. This landmark approval represents a major clinical victory for patients with this aggressive form of breast cancer and reflects years of rigorous clinical research and scientific innovation.
HER2-positive metastatic breast cancer remains one of the most challenging oncological conditions to manage. Approximately one in five breast cancer...
